Boston Scientific stands strong in BRIC zone despite tough economic conditions

According to a report published by Zacks, Boston Scientific is holding its position in the BRIC nations despite uncertain economic conditions, competition, and currency exchange issues. The company also expects positive outcomes from acquisitions and restructuring initiatives. Boston Scientific’s positioning in the developing geographies market improved by 12%, led by a revenue growth of 21% in China in the past quarter. The Interventional Cardiology (IC) subsector of the company’s extensive product range represented a strong sales growth of 11% in Asia with double-digit growth of drug-eluting stent (DES) sales. Promus PREMIER Stent’s sale in China and Japan was the leading contributing factor behind the double-digit growth of the drug-eluting stent (DES) segment. The company is expecting positive results from its cardiology segment, which is heading towards a stable position with growth in the BRIC zone. The business segment is estimated to grow over 15% annually in India, while in China it is expected to double by 2017. The recent acquisition of the American Medical Systems (AMS) urology portfolio from Endo International is likely to create solid growth prospects by portfolio extension and global market expansion as well. The commercial release of company’s rich pipeline products under development will also aid its market growth. However, inefficient performance of pacing and defibrillators business of the company’s portfolio is concerning, along with unfavorable currency movements.